Oral antiplatelet agents, including aspirin, P2Y12 inhibitors, and vorapaxar, significantly reduce mortality and morbidity in patients with cardiovascular disease.
This review summarizes the current evidence and guideline-driven use of oral antiplatelet agents, including aspirin, P2Y12 inhibitors, and vorapaxar, in the management of cardiovascular disease.
Abstract. Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains the most frequently prescribed antiplatelet agent in cardiovascular disease. In patients with acute coronary syndromes (ACS) and in those undergoing angioplasty with stent implantation dual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) receptor antagonist is indicated. The development of the newer ADP P2Y 12 inhibitors prasugrel and ticagrelor has further improved prognosis in ACS patients compared to clopidogrel. Moreover, vorapaxar allows the inhibition of platelet activation by thrombin via protease-activated receptor-1 and has been approved for the use in patients with PAD and in those with a history of myocardial infarction. This review article summarizes the current evidence on oral antiplatelet agents in cardiovascular disease. Keywords: Aspirin, clopidogrel, prasugrel, ticagrelor, vorapaxar, cardiovascular disease
Pultar et al. (Tue,) conducted a review in Cardiovascular disease. Oral antiplatelet agents was evaluated. Oral antiplatelet agents, including aspirin, P2Y12 inhibitors, and vorapaxar, significantly reduce mortality and morbidity in patients with cardiovascular disease.